Allakos Inc. (ALLK): Price and Financial Metrics

Allakos Inc. (ALLK): $5.07

-0.38 (-6.97%)

POWR Rating

Component Grades













Add ALLK to Watchlist
Sign Up

Industry: Biotech



in industry

ALLK Stock Price Chart Interactive Chart >

Price chart for ALLK

ALLK Price/Volume Stats

Current price $5.07 52-week high $8.73
Prev. close $5.45 52-week low $2.54
Day low $5.07 Volume 386,722
Day high $5.45 Avg. volume 989,633
50-day MA $6.63 Dividend yield N/A
200-day MA $5.62 Market Cap 434.41M

Allakos Inc. (ALLK) Company Bio

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.

ALLK Latest News Stream

Event/Time News Detail
Loading, please wait...

ALLK Latest Social Stream

Loading social stream, please wait...

View Full ALLK Social Stream

Latest ALLK News From Around the Web

Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.

Allakos jumps 22% after Q4 update amid bullish views from Piper Sandler

  • Rebounding from a five-month low in the previous session, Allakos (NASDAQ:ALLKgained ~22% on Tuesday after the clinical-stage biotech announced its Q4 2022 results and Piper Sandler launched its coverage with an Overweight rating.
  • As for the Q4 update, upcoming milestones for Redwood City, California, indicate initial data readouts expected for its lead candidate lirentelimab in H2 2023 from two mid-stage studies for atopic dermatitis (AD) and Seeking Alpha | March 7, 2023

Why Allakos Stock Was Heating Up Today

Although Allakos reported a net loss of $43 million in the fourth quarter of 2022, investors were more concerned with the progress of the company's clinical pipeline. More specifically, Allakos reaffirmed today that it expects to report trial results from a pair of ongoing mid-stage studies for its lead compound, lirentelimab, in the second half of 2023. The monoclonal antibody is presently in a phase 2 trial as a treatment for atopic dermatitis and a phase 2b trial for chronic spontaneous urticaria (hives).

Yahoo | March 7, 2023

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos Events Initiated a Phase 2b randomized, double-blind, placebo-cont

Yahoo | March 6, 2023

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

How far off is Allakos Inc. ( NASDAQ:ALLK ) from its intrinsic value? Using the most recent financial data, we'll take...

Yahoo | January 26, 2023

Is Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 15, 2022

Read More 'ALLK' Stories Here

ALLK Price Returns

1-mo -19.91%
3-mo -27.26%
6-mo -8.48%
1-year -18.09%
3-year -13.95%
5-year N/A
YTD -39.79%
2022 -13.99%
2021 -30.07%
2020 46.81%
2019 82.44%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6728 seconds.